Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-17
2011-05-17
Loewe, Sun Jae Y (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S023000
Reexamination Certificate
active
07943661
ABSTRACT:
The invention concerns novel substituted 1,3-diphenylprop-2-en-1-one derivatives, pharmaceutical compositions comprising same, their therapeutic uses, in particular for treating cerebral ischemia. The invention also concerns a method for preparing said derivatives.
REFERENCES:
patent: 3558612 (1971-01-01), Kuhn et al.
patent: 3994955 (1976-11-01), Sprenger
patent: 4190671 (1980-02-01), Vanstone et al.
patent: 4656305 (1987-04-01), Vanstone et al.
patent: 5109025 (1992-04-01), Satoh et al.
patent: 5276058 (1994-01-01), Satoh et al.
patent: 5326670 (1994-07-01), Kotachi et al.
patent: 5523302 (1996-06-01), Cain et al.
patent: 7385082 (2008-06-01), Delhomel et al.
patent: 7547729 (2009-06-01), Caumont-Bertrand et al.
patent: 7566737 (2009-07-01), Delhomel
patent: 7632870 (2009-12-01), Najib et al.
patent: 2005/0171149 (2005-08-01), Najib et al.
patent: 2005/0176808 (2005-08-01), Najib et al.
patent: 2007/0032543 (2007-02-01), Delhomel et al.
patent: 43 27 365 (1995-02-01), None
patent: 0 947 511 (1999-10-01), None
patent: 1 254 658 (2002-11-01), None
patent: 1 254 759 (2002-11-01), None
patent: 2 248 829 (1975-05-01), None
patent: 2 383 157 (1977-08-01), None
patent: 78 06279 (1978-10-01), None
patent: 2 841 900 (2004-01-01), None
patent: 52078856 (1977-07-01), None
patent: WO 95/05358 (1995-02-01), None
patent: WO 98/27970 (1998-07-01), None
patent: WO 00/23073 (2000-04-01), None
patent: WO 01/98291 (2001-12-01), None
patent: 2004/005233 (2004-01-01), None
patent: 2004/005243 (2004-01-01), None
Byrn, et al. “Solid State Chemistry of Drugs”, 2d ed., SSCI, Inc., Ch. 10 Polymorphs, pp. 232-247 (1999).
Pond et al., caplus an 1906:1190.
Pond et al., caplus an 1906:1190 (1906).
Shibata, “Anti-tumorigenic Chalcones”, Stem Cells, vol. 12, 1994, pp. 44-52.
Dimmock et al, “Bioactivities of Chalcones”, Current Medicinal Chemistry, Bentham Science Publishers, vol. 6, No. 12, 1999, pp. 1125-1149.
L'ebreau et al, “Antioxidant Properties of Di-Tert-Butylhydroylated Flavonoids”, Free Radical Biology and Medicine, vol. 29, No. 9, Nov. 1, 2000, pp. 900-912.
Mukherjee et al, “Synthetic and Biological Activity Evaluation Studies on Novel 1,3-Diarylpropenones”, Bioorganic & Medicinal Chemistry, vol. 9, No. 2, 2001, pp. 337-345.
Cheng et al, “Broussochalcone A, a potent antioxidant and effective suppressor of inducible nitric oxide synthase in lipopolysaccharide-activated macrophages”, Biochemical Pharmacology, vol. 61, No. 8, Apr. 15, 2001, pp. 939-946.
Cheng et al, “Antioxidant properties of butein isolated from Dalbergia odorifera”, Biochemica et Biophysics Acta, vol. 1392, No. 2/3, Jun. 15, 1998. pp. 291-299.
Rajakumar et al, “Antioxidant Properties of Phenyl Styryl Ketones”, Free Radical Research, vol. 22, No. 4, 1995, pp. 309-317.
Arty et al, “Synthesis of benzylideneacetophenones and their inhibition of lipid peroxidation”, European Journal of Medicinal Chemistry 2000 France, vol. 35, No. 4, 2000, pp. 449-457.
Database Chemical Abstracts Service, XP002236011, abstract & Zhang et al, “Antioidation of Peurperia lobate isoflavones”, Tongji Yike Dauxe Xeubao, vol. 26, No. 5, 1997, pp. 340-342.
Stoll et al, Chalcone derivatives antagonize interactions between the human oncoprotein NDM2 and p53, Biochemistry, United States Jan. 16, 2001, vol. 40, No. 2, Jan. 16, 2001, pp. 336-344.
Database Chemical Abstracts Service, XP002262904, abstract & Shi et al, “Synthesis of ethyl Flavone(or chalcone)oxyllsobutyrate and its derivatives as potential antilipidemic agents”, Taiwan Yaoxue Zazhi, vol. 27, No. 1-2, 1975, pp. 12-16.
Lebeau et al, “Beneficial effects of different flavonoids, on functional recovery after ischemia and reperfusion in isolated rat heart”, Bioorganic & Medicinal Chemistry Letters, vol. 11, No. 1, Jan. 8, 2001, pp. 23-27.
Patent Abstracts of Japan vol. 014, No. 126, Mar. 9, 1990 & JP 02 003670 A Jan. 9, 1990.
Halliwell, “Oxidants and the central nervous system: some fundamental questions. Ix oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke?”, Acta Neurologica Scandinavica, Supplementum, Denmark 1989, vol. 126, 1989, pp. 23-33.
Office Action dated Feb. 26, 2009, issued in connection with U.S. Appl. No. 10/520,078.
King, Frank D. “Bioisosteres, Conformational Restriction, and Pro-drugs—Case History: An Example of a Conformational Restriction Approach”, Medical Chemistry: Principles and Practice, 1994, Chapter 14, pp. 206-225.
Byrn, et al, “Solid State Chemistry of Drugs”, 2nded., SSCI, Inc., Chapter 10, p. 232-247, 1999.
Sogawa et al, “3,4-Dihydroxychalcones as Potent 5-Lipoxygenase and Cyclooxygenase Inhibitors”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 36, No. 24, 1993, pp. 3904-3909.
Nakamura et al, “Synthesis and Biological Activities of Fluorinated Chalcone Derivativs”, Bioorganic & Medicinal Chemistry, Elsevier Science Ltd, GB, vol. 10, No. 3, Mar. 2002, pp. 699,706.
Calliste et al, “Chalcones: Structural Requirements for Antioxidant, Estrogenic and Antiproliferative Activities”, Anticancer Research, Helenic Anticancer Institute, Athens, GR, vol. 21, No. 6A, 2001, pp. 3949-3956.
Furman et al, “Di-tert-Butylhydroxylated Flavonoids Protect Endothelial Cells Against Oxidized LDL-Induced Cytotocity”, Journal of Biochemical and Molecular Toxicology, Wiley, New York, NY, US, vol. 15, No. 5, 2001, pp. 270-278.
Lim et al, “Synthesis of flavonoids and their effects on aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues”, Journal of Pharmacy and Pharmacology, London, GB, vol. 53, No. 5, May 2001, pp. 653-668.
U.S. Appl. No. 10/520,079, filed Apr. 2005, Najib et al.
U.S. Appl. No. 11/493,040, filed Jul. 2006, Delhomel et al.
Patent Abstracts of Japan, vol. 018, No. 415, Aug. 4, 1994 & JP 06 122623 A, May 6, 1994.
Patent Abstracts of Japan, vol. 012, No. 209, Jun. 15, 1988 & JP 63 010720 A, Jan. 18, 1988.
Haraguchi et al, “Antioxidative and Superoxide Scavenging Activities of Retrochalcones in Glycyrrhiza Inflata”, Bioorganic & Medicinal Chemistry, Elsevier Science Ltd, GB, vol. 6, No. 3, Mar. 1998, pp. 339-347.
Chemical Abstracts Service XP002236041, abstract & Oganesyan et al, “Study of structure-activity (A) interrelations in the flavonoid series. I. Synthesis of chalcome derivatives and quantitative SA analysis”, Khimiko-Farmatseviicheskii Zhurnal, vol. 20, No. 6, 1986, pp. 696-702.
Hsu et al, Structure-Activity Relationships of Substituted Flavonoids. (I), Taiwan-Kexue-Formosanscience, Taipei, TW, vol. 27, No. 1/2, 1973, pp. 23-26.
Szajda et al, “New alkoxycarbonylalkyl oxychalcones and their alpha, beta-dibromo derivatives of potential antimicrobial activity”, Die Pharmazie, Germany, East Mar 1989, vol. 44, No. 3, Mar. 1989. pp. 190-191.
Stoll et al, “Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53”, Biochemistry, American Chemical Society. Easton, PA, US, vol. 40, No. 2, Jan. 16, 2001, pp. 336-344.
Database, Chemical Abstracts Service, XP002271329, abstract & Shi et al, “Synthesis of ethyl flavone (or chalcone) oxyisobutyrate and its derivatives as antilipemic agents”, Taiwan Yaoxue Xazhi, vol. 27, No. 1-2, 1975, pp. 12-16.
Database Chemical Abstracts Service, XP002271330, abstract & Palanowski et al, “Synthesis of potentiao vasoactive compounds. I. phenylacrylophenone derivatives”, Acta Poloniae Pharmaceutica (English Translation), vol. 24, No. 6, 1967, pp. 567-574.
Database, Chemical Abstracts Service, XP002271331, abstract & JP 54 019947 A (Taisho Pharmaceutical Co.) Feb. 15, 1979.
Database, Chemical Abstracts Service, XP002271332, abstract & Safak et al, “Chalcones. II. Synthesis of so
Caumont-Bertrand Karine
Najib Jamila
Genfit
Loewe Sun Jae Y
Nixon & Vanderhye P.C.
LandOfFree
Substituted 1,3-diphenylprop-2-en-1-one derivatives and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1,3-diphenylprop-2-en-1-one derivatives and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1,3-diphenylprop-2-en-1-one derivatives and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2666817